Company
Hologic
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
57
510(k), De Novo and PMA
Device trials
19
As lead sponsor, any status
Adverse event reports
1,536
Received Nov 1, 2025 to Nov 19, 2026
Recall records
72
One per recalled product
Hologic is on our company list and was publicly traded as HOLX. Naming a company here is not a recommendation of it or of any security.
Financing
No longer publicly listed. Below are the private placements it reported to the SEC on Form D, including any from its years as a public company.
Formerly public as HOLX. It filed to stop SEC reporting on Apr 17, 2026, which usually follows an acquisition or a take-private, so it no longer publishes financial statements.
Total raised (reported)
$450M
1 Form D offering, 2010 to 2010
Equity
$0
Stock sold for cash
Debt and convertible notes
$450M
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: debt, $450M raised of $450M sought, first sale Nov 23, 2010, 8 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Nov 23, 2010 | Debt | $450M | $450M | 8 | Rule 506 | Form D ↗Nov 24, 2010 |
Company details
From the company's latest Form D.
- Legal name
- HOLOGIC INC
- Headquarters
- Bedford, Massachusetts
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Over $100,000,000
- Industry filed under
- Other Health Care
- SEC filer
- CIK 859737 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Mark CaseyExecutive Officer
- David LaVance, Jr.Director
- Glenn MuirExecutive Officer, Director
- Wayne WilsonDirector
- John CummingExecutive Officer, Director
- Elaine UllianDirector
- Peter SoltaniExecutive Officer
- Steve WilliamsonExecutive Officer
- Lawrence LevyDirector
- Jay SteinExecutive Officer
- David BradyExecutive Officer
- Sally CrawfordDirector
- Nancy LeamingDirector
- Robert CascellaExecutive Officer, Director
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Hologic.
Latest FDA decisions
The 8 newest of 57 since 2015.
- I-View®510(k)
K254090 · Decided Sep 2, 2026 · 257 days after receipt
Device type: Full Field Digital, System, X-Ray, Mammographic (MUE) · Radiology & Imaging
K262792 · Decided Aug 12, 2026 · 6 days after receipt
Device type: Instrument, Biopsy (KNW) · GI, Urology & Nephrology
K253634 · Decided Jun 17, 2026 · 210 days after receipt
Device type: Electrosurgical, Cutting & Coagulation & Accessories (GEI) · General & Plastic Surgery
K251868 · Decided Sep 25, 2025 · 99 days after receipt
Device type: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System (PCH) · Laboratory Medicine & Pathology
K251993 · Decided Sep 25, 2025 · 90 days after receipt
Device type: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System (PCH) · Laboratory Medicine & Pathology
- Genius AI Detection 2.0510(k)
K243341 · Decided Jul 31, 2025 · 279 days after receipt
Device type: Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer (QDQ) · Radiology & Imaging
- Aptima SARS-CoV-2 Assay510(k)
K243396 · Decided Feb 13, 2025 · 105 days after receipt
Device type: Respiratory Specimen Nucleic Acid Sars-Cov-2 Test (QQX) · Laboratory Medicine & Pathology
- Aptima CMV Quant Assay510(k)
K243935 · Decided Jan 17, 2025 · 28 days after receipt
Device type: Cytomegalovirus (Cmv) Dna Quantitative Assay (PAB) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational DeviceActive, not recruiting
NCT06636539 · 75 participants (planned) · Start Oct 14, 2024 · Primary completion Nov 5, 2026
Device: CEM Software in New Mammography Device · For: Breast Screening
Sites: Houston, Texas; Sterling, Virginia
- Prospective Case Collection Study for New Mammography TechnologiesActive, not recruiting
NCT05199701 · 7,500 participants (planned) · Start Dec 10, 2021 · Primary completion Nov 5, 2026
Device: Mammography · For: Mammography
Sites: Gilbert, Arizona; Scottsdale, Arizona; Coral Gables, Florida · 15 sites in all
NCT03611543 · 443 participants · Start Oct 20, 2016 · Primary completion Jun 18, 2018
Device: Standard of Care Flat Paddle; Investigational Curved Paddle · For: Breast Cancer
Sites: Stamford, Connecticut; Rochester, New York; Addison, Texas · 4 sites in all
NCT00971087 · 3,521 participants · Start Sep 2009 · Primary completion Sep 2011
Device: Hologic Selenia Dimensions Digital Breast Tomosynthesis System · For: Breast Cancer
Sites: Scottsdale, Arizona; Newport Beach, California; Sacramento, California · 22 sites in all
NCT03300206 · 525 participants · Start Sep 13, 2017 · Primary completion Mar 19, 2019
Device: Breast Biopsy · For: Breast Cancer Female
Sites: Phoenix, Arizona; Kensington, Maryland; St Louis, Missouri · 7 sites in all
NCT03456583 · 500 participants · Start Nov 20, 2017 · Primary completion Nov 20, 2018
Device: Brevera Breast Biopsy System · For: Breast Cancer Female
Sites: Montpellier, France; Tübingen, Germany; Milan, Italy · 6 sites in all
Reports received
1,536
Received Nov 1, 2025 to Nov 19, 2026. Includes 3 of another or unstated type.
Malfunction reports
783
51% of reports
Injury reports
747
49% of reports
Death reports
3
0.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 18 | 22 | 0 | 0 |
| Jan 24 | 12 | 34 | 0 | 0 |
| Feb 24 | 47 | 33 | 0 | 0 |
| Mar 24 | 22 | 51 | 0 | 0 |
| Apr 24 | 22 | 37 | 1 | 0 |
| May 24 | 23 | 23 | 0 | 0 |
| Jun 24 | 30 | 44 | 0 | 0 |
| Jul 24 | 19 | 22 | 1 | 0 |
| Aug 24 | 30 | 54 | 1 | 0 |
| Sep 24 | 40 | 59 | 0 | 0 |
| Oct 24 | 40 | 48 | 0 | 0 |
| Nov 24 | 66 | 41 | 3 | 1 |
| Dec 24 | 28 | 47 | 0 | 0 |
| Jan 25 | 34 | 55 | 3 | 0 |
| Feb 25 | 18 | 58 | 0 | 0 |
| Mar 25 | 41 | 187 | 1 | 0 |
| Apr 25 | 35 | 83 | 0 | 0 |
| May 25 | 25 | 67 | 1 | 0 |
| Jun 25 | 29 | 67 | 1 | 0 |
| Jul 25 | 37 | 45 | 0 | 0 |
| Aug 25 | 28 | 57 | 2 | 0 |
| Sep 25 | 27 | 45 | 1 | 0 |
| Oct 25 | 42 | 47 | 1 | 0 |
| Nov 25 | 35 | 32 | 1 | 0 |
| Dec 25 | 39 | 44 | 0 | 0 |
| Jan 26 | 37 | 32 | 0 | 0 |
| Feb 26 | 35 | 43 | 0 | 0 |
| Mar 26 | 60 | 48 | 0 | 0 |
| Apr 26 | 43 | 34 | 0 | 0 |
| May 26 | 51 | 141 | 0 | 0 |
| Jun 26 | 73 | 71 | 0 | 0 |
| Jul 26 | 63 | 50 | 0 | 0 |
| Aug 26 | 84 | 47 | 0 | 2 |
| Sep 26 | 95 | 83 | 0 | 1 |
| Oct 26 | 168 | 122 | 2 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- BIOZORB142
- NOVASURE132
- 3DIMENSIONS111
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2167-2026 · Started Apr 8, 2026 · Posted by FDA May 12, 2026
Reason given: Complaints have been received of systems developing loose, missing, or broken internal bolts over time.
Cause as FDA categorized it: Device Design · Device type: Full Field Digital, System, X-Ray, Mammographic (MUE)
Z-2168-2026 · Started Apr 8, 2026 · Posted by FDA May 12, 2026
Reason given: Complaints have been received of systems developing loose, missing, or broken internal bolts over time.
Cause as FDA categorized it: Device Design · Device type: Digital Breast Tomosynthesis (OTE)
Z-1949-2026 · Started Mar 23, 2026 · Posted by FDA Apr 24, 2026
Reason given: It was identified that certain devices were being operated outside the validated and FDA-cleared display configuration due to user modification of the manufacturer-installed settings. Modifications included disabling Barco Application Appearance Manager (AAM), altering calibration and compliance parameters, and...
Cause as FDA categorized it: Software design · Device type: Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm (QYV)
- Brand Name: Aptima HPV Assay Product Name: Aptima HPV Assay Model/Catalog Number: 303585 Product Description: Aptima HPV assay Component: NoOpen, Classified
Z-1586-2026 · Started Feb 18, 2026 · Posted by FDA Mar 19, 2026
Reason given: Due to product exhibiting potential to generate either invalid or false negative results.
Cause as FDA categorized it: Under Investigation by firm · Device type: Kit, Rna Detection, Human Papillomavirus (OYB)
Z-1314-2026 · Started Dec 15, 2025 · Posted by FDA Feb 6, 2026
Reason given: Presence of particulates in affected devices that can be deposited into breast tissue during use.
Cause as FDA categorized it: Under Investigation by firm · Device type: Instrument, Biopsy (KNW)
- ThinPrep CytoLyt Solution. Buffered Cell Wash Solution.Open, Classified
Z-1093-2026 · Started Dec 12, 2025 · Posted by FDA Jan 15, 2026
Reason given: Fungal contamination of affected lot with Parengyodontium album.
Cause as FDA categorized it: Under Investigation by firm · Device type: Preservative, Cytological (LEA)
Z-1170-2025 · Started Jan 15, 2025 · Posted by FDA Feb 13, 2025
Reason given: Devices presented a condition in which the inner needle separated from the hub and produced a longer throw of the inner needle or dislodgement.
Cause as FDA categorized it: Process control · Device type: Instrument, Biopsy (KNW)
Z-1095-2025 · Started Jan 8, 2025 · Posted by FDA Feb 4, 2025
Reason given: Three lots of Rapid fFN Specimen Collection kit (901164, 901165, and 904850) contain Rapid fFN Specimen Collection Tubes which may be empty, underfilled, or overfilled with extraction buffer. The transport tubes are used with the Fetal Fibronectin Enzyme Immunoassay and Rapid fFN for the TLiIQ System which aids in...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Device, Specimen Collection (LIO)
Showing the 8 newest of 72 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.